Etoposide and Neumega drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Etoposide (etoposide) and Neumega (oprelvekin). Common drug interactions include blindness among females and sudden cardiac death among males.

The phase IV clinical study analyzes what interactions people have when they take Etoposide and Neumega. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

What is Neumega?

Neumega has active ingredients of oprelvekin. eHealthMe is studying from 822 Neumega users. Check the latest studies of Neumega.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

14 people who take Etoposide and Neumega together, and have interactions are studied.

Etoposide and Neumega drug interactions.

What are the common drug interactions of Etoposide and Neumega, by gender? *:

female:

Blindness
Coma (state of unconsciousness lasting more than six hours)
Fluid retention (an abnormal accumulation of fluid in the blood)
Papilloedema (optic disc swelling)
Platelet count decreased
Pulse absent
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood creatinine increased

male:

Sudden cardiac death
Anion gap decreased
Conduction disorder (serious disorder of the heart not responses proper to impulses)
Dyspnoea (difficult or laboured respiration)
Haematocrit decreased
Haemoglobin decreased
Oedema (fluid collection in tissue)
Pyrexia (fever)
Red blood cell count decreased
Red cell distribution width increased

What are the common drug interactions of Etoposide and Neumega, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Coma (state of unconsciousness lasting more than six hours)
Platelet count decreased
Pulse absent
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood alkaline phosphatase increased
Blood creatinine increased
Blood pressure decreased
Depressed level of consciousness
Heart rate increased

20-29:

n/a

30-39:

Blindness
Fluid retention (an abnormal accumulation of fluid in the blood)
Papilloedema (optic disc swelling)

40-49:

n/a

50-59:

Sudden cardiac death
Anion gap decreased
Cardiac arrest
Albumin globulin ratio decreased
Blood osmolarity decreased
Conduction disorder (serious disorder of the heart not responses proper to impulses)
Haematocrit decreased
Haemoglobin decreased
Red blood cell count decreased
Red cell distribution width increased

60+:

Confusion
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Weight increased
Gait abnormal
Lethargy (tiredness)
Blood urea increased
Dyspnoea (difficult or laboured respiration)
Oedema (fluid collection in tissue)
Pyrexia (fever)
Rigors (an episode of shaking or exaggerated shivering)

What are the existing conditions these people have? *

Hodgkin's Lymphoma (cancer originating from white blood cells): 1 person, 7.14%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Etoposide and Neumega?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously